论文部分内容阅读
目的观察分析乳腺癌新辅助化疗的临床效果及其与TopoⅡ变化的关系。方法选取80例乳腺癌患者,40例患者已发生肿瘤转移(转移组),40例未发生肿瘤转移(未转移组),均采用TEC方案进行新辅助化疗,并在化疗前后进行拓扑异构酶Ⅱ(TopoⅡ)检测,观察两组患者TopoⅡ表达阳性情况,治疗效果,化疗后TopoⅡ表达率降低情况及治疗有效组与治疗无效组化疗后TopoⅡ表达率降低情况。结果 40例转移组患者TopoⅡ阳性表达率为95.00%,未转移组表达阳性率为87.50%,两组差异无统计学意义。转移组治疗总有效率为40.00%,化疗后TopoⅡ表达率降低为10.53%,对照组分别为67.50%,31.43%,转移组显著低于未转移组,差异有统计学意义(P﹤0.05)。80例患者中,43例治疗有效,37例治疗无效,有效组13例(32.50%)TopoⅡ表达率降低,无效组2例(6.06%)降低,差异有统计学意义(P﹤0.05)。结论对乳腺癌患者采用新辅助化疗可使肿瘤面积缩小,为患者手术切除创造条件,乳腺癌患者TopoⅡ均呈现高表达,化疗后TopoⅡ表达率降低不显著,但TopoⅡ表达率降低与患者乳腺癌是否发生转移及化疗效果具有一定相关性。
Objective To observe the clinical effect of neoadjuvant chemotherapy for breast cancer and its relationship with Topo Ⅱ. Methods Eighty patients with breast cancer were enrolled in this study. Tumor metastasis (metastasis group) occurred in 40 patients and no tumor metastasis in 40 patients (no metastasis group). Neoadjuvant chemotherapy was performed with TEC regimen and topoisomerase (TopoⅡ). The positive expression of TopoⅡ in both groups were observed. The curative effect, the decrease of Topo Ⅱ expression after chemotherapy, and the decrease of Topo Ⅱ expression in the treatment group and the ineffective group were observed. Results The positive rate of Topo Ⅱ in 40 cases of metastasis was 95.00%, and the positive rate of non-metastatic group was 87.50%. There was no significant difference between the two groups. The total effective rate was 40.00% in the metastatic group, 10.53% in the metastatic group, and 67.50% and 31.43% in the control group, respectively. The metastasis group was significantly lower than the non-metastatic group (P <0.05). Among the 80 patients, 43 cases were effective and 37 cases were ineffective. TopoⅡexpression was decreased in 13 cases (32.50%) in effective group and 2 cases (6.06%) in invalid group, with significant difference (P <0.05). Conclusion Neoadjuvant chemotherapy can reduce the tumor area in patients with breast cancer and create favorable conditions for surgical resection. Topo Ⅱ expression in breast cancer patients is high, while Topo Ⅱ expression rate is not significantly reduced after chemotherapy. However, the decrease of Topo Ⅱ expression is not associated with breast cancer Metastasis and chemotherapy have some relevance.